PCM
NUVB icon

Pavaki Capital Management’s Nuvation Bio NUVB Stock Holding History

Pavaki Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Hold
30,000
– – 0.06% 137
2026
Q1 		$129K Buy
+30,000
New +$167K 0.05% 142

Other funds holding NUVB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Pavaki Capital Management's NUVB Position: Q2 2026 in Review

Pavaki Capital Management held its Nuvation Bio (NUVB) position steady in Q2 2026 at 30,000 shares worth $170K. The position accounts for 0.06% of the portfolio, ranked #137.

Pavaki Capital Management first reported a position in NUVB in Q1 2026 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Pavaki Capital Management held 30,000 shares of Nuvation Bio worth $170K as of Q2 2026.
  • Pavaki Capital Management left its Nuvation Bio share count unchanged in Q2 2026.
  • Nuvation Bio made up 0.06% of Pavaki Capital Management's portfolio in Q2 2026, its #137 holding.
  • Pavaki Capital Management first reported a position in Nuvation Bio in Q1 2026 and has held it in 2 quarters since.
  • 221 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.